Startup’s alternative to CAR-T immunotherapy: “PAR-T” therapy
Tychon Biosciences' PAR-T therapy uses nanorings to link T-cells to cancer-seeking antigens - sidestepping any genetic engineering.
invenshure
Tychon Biosciences' PAR-T therapy uses nanorings to link T-cells to cancer-seeking antigens - sidestepping any genetic engineering.